Document is current
Any future updates will be listed below
-
Authors
Hahn, Andrew W. https://orcid.org/0000-0002-4153-205X
Koutroumpakis, Efstratios https://orcid.org/0000-0002-6757-6480
Narayan, Vivek https://orcid.org/0000-0002-8205-738X
Aparicio, Ana https://orcid.org/0000-0003-0900-0923
-
Funding
Funding for this research was provided by:
Prostate Cancer Foundation (21YOUN33)
- License Information
-
More Information
Article History
Received: 19 April 2024
Revised: 1 May 2024
Accepted: 15 May 2024
First Online: 25 May 2024
Competing interests
: AWH reports advisory board consulting for Johnson & Johnson Innovative Medicine, Intellisphere, Exelixis, Eisai, and Pfizer; honoraria from Medscape and Binaytara Foundation; travel support from DAVA Oncology, and institutional research funding from Bayer and Eisai. VK reports consulting for Janssen Oncology, Pfizer, Regeneron, Merck, Myovant, Eisai, Aveo, AstraZeneca, Xencor, and Exelixis; and institutional research funding from Pfizer, Merck, Janssen, Xencor, Bristol-Myers Squibb, and Regeneron. AA reports consulting for Amgen, Astellas Pharma, Astra Zeneca Pharmaceuticals, Bayer, Bristol-Myers Squibb Pharmaceuticals, Daiichi Sankyo, Genzyme, Janssen Pharmaceuticals, Pfizer, and Sanofi; and institutional research funding from AstraZeneca Pharmaceuticals, Janssen Pharmaceuticals, and Polaris Pharmaceuticals.
Free to read: This content has been made available to all.
